NO20071428L - Kombinasjon inneholdende ZD6474 og Imatinib - Google Patents

Kombinasjon inneholdende ZD6474 og Imatinib

Info

Publication number
NO20071428L
NO20071428L NO20071428A NO20071428A NO20071428L NO 20071428 L NO20071428 L NO 20071428L NO 20071428 A NO20071428 A NO 20071428A NO 20071428 A NO20071428 A NO 20071428A NO 20071428 L NO20071428 L NO 20071428L
Authority
NO
Norway
Prior art keywords
imatinib
human
angiogenic
warm
producing
Prior art date
Application number
NO20071428A
Other languages
English (en)
Norwegian (no)
Inventor
Stephen Robert Wedge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0421438A external-priority patent/GB0421438D0/en
Priority claimed from GB0506726A external-priority patent/GB0506726D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20071428L publication Critical patent/NO20071428L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20071428A 2004-09-27 2007-03-16 Kombinasjon inneholdende ZD6474 og Imatinib NO20071428L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0421438A GB0421438D0 (en) 2004-09-27 2004-09-27 Combination therapy
GB0506726A GB0506726D0 (en) 2005-04-01 2005-04-01 Combination therapy
PCT/GB2005/003673 WO2006035204A2 (en) 2004-09-27 2005-09-23 Combination comprising zd6474 and an imatinib

Publications (1)

Publication Number Publication Date
NO20071428L true NO20071428L (no) 2007-04-02

Family

ID=35924044

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071428A NO20071428L (no) 2004-09-27 2007-03-16 Kombinasjon inneholdende ZD6474 og Imatinib

Country Status (11)

Country Link
US (2) US20080119479A1 (enExample)
EP (1) EP1804802A2 (enExample)
JP (1) JP2008514577A (enExample)
KR (1) KR20070072543A (enExample)
AU (1) AU2005288737B2 (enExample)
BR (1) BRPI0516052A (enExample)
CA (1) CA2578956A1 (enExample)
IL (1) IL181609A0 (enExample)
MX (1) MX2007003505A (enExample)
NO (1) NO20071428L (enExample)
WO (1) WO2006035204A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
DE602004032310D1 (de) * 2003-02-13 2011-06-01 Astrazeneca Ab Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
JP2007526886A (ja) * 2003-07-10 2007-09-20 アストラゼネカ アクチボラグ 血管新生および/または血管透過性増大に関連する疾患の処置における、プラチナ系抗腫瘍剤および任意の電離放射線と組み合わせてのキナゾリン誘導体zd6474の使用
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
CA2631764A1 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy
EP3352107B1 (en) 2008-03-03 2025-10-22 NIKE Innovate C.V. Interactive athletic equipment system
US8628453B2 (en) 2008-12-05 2014-01-14 Nike, Inc. Athletic performance monitoring systems and methods in a team sports environment
US20100184564A1 (en) 2008-12-05 2010-07-22 Nike, Inc. Athletic Performance Monitoring Systems and Methods in a Team Sports Environment
US8231506B2 (en) 2008-12-05 2012-07-31 Nike, Inc. Athletic performance monitoring systems and methods in a team sports environment
CA2955632A1 (en) 2010-11-10 2012-05-18 Nike Innovate C.V. Systems and methods for time-based athletic activity measurement and display
EP2676212B1 (en) 2011-02-17 2022-03-16 NIKE Innovate C.V. Selecting and correlating physical activity data with image data
KR101386697B1 (ko) 2012-06-18 2014-04-18 아주대학교산학협력단 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
CA3280124A1 (en) 2013-07-31 2025-10-31 Avalyn Pharma Inc. Aerosol imatinib compounds and uses thereof
KR101778004B1 (ko) 2015-06-22 2017-09-15 (주) 에빅스젠 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물
EP3658190B1 (en) 2017-07-26 2025-10-01 Oncosol Limited Liquid dosage forms of imatinib

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1244647E (pt) * 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
AU2003231098A1 (en) * 2002-04-25 2003-11-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
AU2003249000B2 (en) * 2002-08-09 2007-04-05 Astrazeneca Ab Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
DE602004032310D1 (de) * 2003-02-13 2011-06-01 Astrazeneca Ab Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11
JP2007526886A (ja) * 2003-07-10 2007-09-20 アストラゼネカ アクチボラグ 血管新生および/または血管透過性増大に関連する疾患の処置における、プラチナ系抗腫瘍剤および任意の電離放射線と組み合わせてのキナゾリン誘導体zd6474の使用
EP1796672A1 (en) * 2004-09-27 2007-06-20 AstraZeneca AB Cancer combination therapy comprising azd2171 and imatinib
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
CA2631764A1 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed

Also Published As

Publication number Publication date
MX2007003505A (es) 2007-05-10
KR20070072543A (ko) 2007-07-04
EP1804802A2 (en) 2007-07-11
WO2006035204A3 (en) 2006-10-19
AU2005288737A1 (en) 2006-04-06
US20100069398A1 (en) 2010-03-18
IL181609A0 (en) 2007-07-04
CA2578956A1 (en) 2006-04-06
BRPI0516052A (pt) 2008-08-19
AU2005288737B2 (en) 2008-08-14
WO2006035204A2 (en) 2006-04-06
US20080119479A1 (en) 2008-05-22
JP2008514577A (ja) 2008-05-08

Similar Documents

Publication Publication Date Title
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
NO20060307L (no) Anvendelse av kinoazolinderivatet ZD6474 kombinert med platinaforbindelser og eventuelt ioniserende straling i behandling av sykdommer assosoiert med angiogenese og/eller okt vaskulaert permeabilitet
NO20072167L (no) Kombinasjon omfattende ZD6474 og et antiandrogen
DK1551409T3 (da) Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer
CY1111547T1 (el) Συνδυασμος zd6474 και πεμετρεξεδης
NO20050528L (no) Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft
WO2006035204A3 (en) Combination comprising zd6474 and an imatinib
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
NO20076657L (no) Kombinasjonsterapi av cancer med AZD2171 og gemcitabin
BR0309226A (pt) Métodos para a produção de um efeito de danificação vascular em um animal de sangue quente, e para o tratamento de um câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, usos de zd6126 ou de um seu sal farmaceuticamente aceitável, e de zd1839 ou de um seu sal farmaceuticamente aceitável
NO20056170L (no) Kreftkombinasjonsterapi omfattende AZD2171 of ZD1839
NO20064753L (no) Kombinasjonsterapi
NO20064755L (no) Kombinasjonsterapi
WO2005092385A3 (en) Combination therapy of azd2171 and a taxane
NO20051601L (no) Kombinasjonsterapi med gemcitabin og zd6126

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application